Solriamfetol for Attention-Deficit/Hyperactivity Disorder in Adults: A Double-Blind Placebo-Controlled Pilot Study
Conclusions: Solriamfetol may be a novel and effective treatment for the management of ADHD in adults. Further replication in larger trials is indicated.Trial Registration: ClinicalTrials.gov identifier: NCT04839562.PMID:37819836 | DOI:10.4088/JCP.23m14934
Source: Journal of Clinical Psychiatry - Category: Psychiatry Authors: Craig B H Surman Daniel M Walsh Nora Horick Maura DiSalvo Chloe Hutt Vater Daniel Kaufman Source Type: research
More News: ADHD | Brain | Cardiology | Cardiovascular | Gastroenterology | Headache | Heart | Hyperactivity | Insomnia | Migraine | Neurology | Psychiatry | Sleep Disorders | Sleep Medicine | Statistics | Study